AACR 2023 | TALENT: tislelizumab with anlotinib and XELOX in gastric carcinoma

Yongqian Shu, MD, PhD, Nanjing Medical University, Nanjing, China, discusses results from the Phase I/IIa TALENT study (NCT04963088) of tislelizumab combined with anlotinib and XELOX chemotherapy in patients with advanced gastric carcinoma. The maximum tolerated dose was determined the Phase I portion, whereas the dose was administered in Phase II. The therapeutic regimen produced promising response rates and an manageable toxicity profile was additionally reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.